EX-VIVO ANALYSIS OF HUMAN SERUM ALBUMIN ACTS AS A DRUG DELIVERY AGAINST MCF-7 CELL LINE

Researchers in the field of nanomedicine have recently paid more attention to drug delivery systems based on nanotechnology because they can achieve ideal drug release and biodistribution. Serum albumin-based nano vehicles have been extensively created and studied due to their notable biological properties and many other materials that are utilized to prepare drug delivery vehicles for efficient cancer treatment. One of these is human serum albumin that is a remarkable promising carrier as an anti-cancer agent. HSA enjoys advantages such as long half-life, repeated recycling, and specific accumulation. HSA includes a number of binding pockets where different ligands, including fatty acids and ions, can bind, giving medications the choice of non-covalent binding sites. Moreover, HSA has lengthened the half-life of medications, lessen renal drug clearance and aid in drug accumulation in particular tumor tissues. HSA offers a promising chance to distribute well-known drugs in a novel method. Brucine is a plant alkaloid compound that was extracted from a fresh leaf of Wrightia tinctoria. Silver nano particles were synthesized by adding silver nitrate with brucine solution. Characterization of nano particles were done by using UV-vis Spectrophotometer, SEM and FTIR. Bioconjugation of HSA with Phyto therapeutic agent capped Ag-NPs were performed and studied in this review. Human serum albumin as a drug delivery vehicle against MCF-7 breast cancer cell line was performed and analyzed in ex-vivo method. The results suggest that Phyto therapeutic agent capped Ag-NPs coated with HSA can be employed as a practical drug delivery system in cancer treatment.